Literature DB >> 32399136

Ability of human umbilical cord mesenchymal stem cells to repair chemotherapy-induced premature ovarian failure.

Jian Shen1, Dai Cao1, Jing-Li Sun2.   

Abstract

BACKGROUND: Premature ovarian insufficiency (POI) and premature ovarian failure (POF) have become one of the major problems threatening women of childbearing age. Studies have shown that stem cells transplanted from bone marrow, umbilical cord, peripheral blood and amniotic fluid can migrate and proliferate to the ovary, promote ovarian function repair, increase the number of follicles and granulosa cells at all levels of ovary, improve endocrine function, and can differentiate into oocytes in specific ovarian environment to restore fertility to some extent. AIM: To study the ability of human umbilical cord mesenchymal stem cells (hUCMSCs) to repair ovarian injury after chemotherapy.
METHODS: A total of 110 female BALB/c mice (aged 7-8 wk old) with body masses of 16.0-20.0 g were selected. The mice were fed until 12 wk of age, and cyclophosphamide was administered by intraperitoneal injection for 14 consecutive days to induce premature ovarian failure in mice. Seventy-five mice with estrous cycle disorder were screened and randomly divided into 3 groups according to their body weight: model group, positive control group and hUCMSC group, and each group had 25 mice. Another 25 mice were used as negative controls. The mice in the hUCMSC group were injected with hUCMSCs in the tail vein, and the mice in the positive control group were given an oestradiol valerate solution and a medroxyprogesterone acetate solution in the tail vein. On the 1st, 15th, 30th, 45th, and 60th days after intravenous administration, vaginal smears were made to monitor the estrous cycles of the mice. The ovaries were weighed, and pathological sections were made to observe the morphology of the follicles; blood samples were collected to monitor the concentration of sex hormones (oestradiol and follicle-stimulating hormone).
RESULTS: The estrous cycles of the model group mice were disrupted throughout the experiment. Mice in the hUCMSC group and the positive control group resumed normal estrous cycles. The ovarian weight of the model group mice continued to decline. The ovarian weight of the hUCMSC group mice and the positive control group mice decreased first and then gradually increased, and the ovarian weight of the hUCMSC group mice was heavier than that of the positive control group mice. The difference was statistically significant (P < 0.05). Compared with the negative control group, the model group experienced a decrease in oestradiol and an increase in follicle-stimulating hormone, and the difference was statistically significant (P < 0.05). Compared with the model group, the hUCMSC and positive control groups experienced a slight increase in oestradiol and a decrease in follicle-stimulating hormone; the difference was statistically significant (P < 0.05). The pathological examination revealed that the mouse ovaries from the model group were atrophied, the volume was reduced, the cortical and medullary structures were disordered, the number of follicles at all stages was significantly reduced, the number of atretic follicles increased, the number of primordial follicles and corpus luteum significantly decreased, and the corpus luteum had an irregular shape. Compared with those of the model group, the lesions of the hUCMSC and positive control groups significantly improved.
CONCLUSION: hUCMSCs can repair ovarian tissue damaged by chemotherapy to a certain extent, can improve the degree of apoptosis in ovarian tissue, and can improve the endocrine function of mouse ovaries. ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Endocrine function; Ovarian injury; Premature ovarian failure; Repair; Umbilical cord mesenchymal stem cells

Year:  2020        PMID: 32399136      PMCID: PMC7202924          DOI: 10.4252/wjsc.v12.i4.277

Source DB:  PubMed          Journal:  World J Stem Cells        ISSN: 1948-0210            Impact factor:   5.326


  30 in total

1.  Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue.

Authors:  Susanne Kern; Hermann Eichler; Johannes Stoeve; Harald Klüter; Karen Bieback
Journal:  Stem Cells       Date:  2006-01-12       Impact factor: 6.277

2.  CD105(+) cells from Wharton's jelly show in vitro and in vivo myogenic differentiative potential.

Authors:  Maria Teresa Conconi; Patrizia Burra; Rosa Di Liddo; Chiara Calore; Michela Turetta; Silvia Bellini; Patrizio Bo; Gastone G Nussdorfer; Pier Paolo Parnigotto
Journal:  Int J Mol Med       Date:  2006-12       Impact factor: 4.101

Review 3.  Immunomodulation by mesenchymal stem cells and clinical experience.

Authors:  K Le Blanc; O Ringdén
Journal:  J Intern Med       Date:  2007-11       Impact factor: 8.989

4.  Comparison between isolation protocols highlights intrinsic variability of human umbilical cord mesenchymal cells.

Authors:  Fernanda Vieira Paladino; Joana Silveira Peixoto-Cruz; Carolina Santacruz-Perez; Anna Carla Goldberg
Journal:  Cell Tissue Bank       Date:  2015-07-09       Impact factor: 1.522

Review 5.  Mesenchymal Stem Cells (MSCs) Therapy for Recovery of Fertility: a Systematic Review.

Authors:  Zahra Fazeli; Atieh Abedindo; Mir Davood Omrani; Sayyed Mohammad Hossein Ghaderian
Journal:  Stem Cell Rev Rep       Date:  2018-02       Impact factor: 5.739

Review 6.  Primary ovarian insufficiency.

Authors:  Michel De Vos; Paul Devroey; Bart C J M Fauser
Journal:  Lancet       Date:  2010-08-11       Impact factor: 79.321

7.  Bone marrow mesenchymal stem cell transplantation improves ovarian function and structure in rats with chemotherapy-induced ovarian damage.

Authors:  X Fu; Y He; C Xie; W Liu
Journal:  Cytotherapy       Date:  2008       Impact factor: 5.414

8.  Female reproductive decline is determined by remaining ovarian reserve and age.

Authors:  Pawel Wilkosz; Gareth D Greggains; Tom G Tanbo; Peter Fedorcsak
Journal:  PLoS One       Date:  2014-10-13       Impact factor: 3.240

9.  Nanotechnology for Treatment of Glioblastoma Multiforme.

Authors:  Justin S Michael; Bong-Seop Lee; Miqin Zhang; John S Yu
Journal:  J Transl Int Med       Date:  2018-10-09

10.  Predisposing Factors for Chemotherapy-induced Nephrotoxicity in Patients with Advanced Esophageal Cancer Who Received Combination Chemotherapy with Docetaxel, Cisplatin, and 5-fluorouracil.

Authors:  Junichi Mohri; Chikatoshi Katada; Marie Ueda; Mitsuhiro Sugawara; Keishi Yamashita; Hiromitsu Moriya; Shouko Komori; Kazushige Hayakawa; Wasaburo Koizumi; Koichiro Atsuda
Journal:  J Transl Int Med       Date:  2018-03-28
View more
  8 in total

Review 1.  Transplantation of human umbilical cord mesenchymal stem cells to treat premature ovarian failure.

Authors:  Oldouz Shareghi-Oskoue; Leili Aghebati-Maleki; Mehdi Yousefi
Journal:  Stem Cell Res Ther       Date:  2021-08-11       Impact factor: 8.079

2.  Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Improve Ovarian Function and Proliferation of Premature Ovarian Insufficiency by Regulating the Hippo Signaling Pathway.

Authors:  Zhongkang Li; Mingle Zhang; Jiahua Zheng; Yanpeng Tian; Huihui Zhang; Yi Tan; Qian Li; Jingkun Zhang; Xianghua Huang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-12       Impact factor: 5.555

3.  Umbilical Cord Mesenchymal Stem Cells Ameliorate Premature Ovarian Insufficiency in Rats.

Authors:  Meiliang Zhang; Tingting Xie; Weiyou Dai; Bo Zhao; Yaqin Zheng; Jianmiao Hu; Ruolang Pan; Liang Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-30       Impact factor: 2.650

Review 4.  Is It Possible to Treat Infertility with Stem Cells?

Authors:  P Petric; E Vrtacnik-Bokal; M Stimpfel
Journal:  Reprod Sci       Date:  2021-04-08       Impact factor: 3.060

5.  Human Umbilical Cord Mesenchymal Stem Cells Improve Ovarian Function in Chemotherapy-Induced Premature Ovarian Failure Mice Through Inhibiting Apoptosis and Inflammation via a Paracrine Mechanism.

Authors:  Taoran Deng; Jing He; Qingyun Yao; Linjing Wu; Liru Xue; Mingfu Wu; Dongcheng Wu; Changyong Li; Yufeng Li
Journal:  Reprod Sci       Date:  2021-03-09       Impact factor: 3.060

Review 6.  Application of Perinatal Derivatives in Ovarian Diseases.

Authors:  Anna Lange-Consiglio; Emanuele Capra; Valentina Herrera; Ingrid Lang-Olip; Peter Ponsaerts; Fausto Cremonesi
Journal:  Front Bioeng Biotechnol       Date:  2022-01-24

Review 7.  Therapeutic Potential of HUMSCs in Female Reproductive Aging.

Authors:  Qiaojuan Mei; Hongbei Mou; Xuemei Liu; Wenpei Xiang
Journal:  Front Cell Dev Biol       Date:  2021-05-10

Review 8.  Making More Womb: Clinical Perspectives Supporting the Development and Utilization of Mesenchymal Stem Cell Therapy for Endometrial Regeneration and Infertility.

Authors:  Michael Strug; Lusine Aghajanova
Journal:  J Pers Med       Date:  2021-12-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.